Background: We aimed to study the plasma adiponectin level as a predictor of
Egyptian type 2 diabetes with and without metabolic syndrome. Subjects and
methods: This study was carried out on 70 humans divided into three groups .
Group I included twenty five type 2 diabetic patients with metabolic syndrome (10
males and 15 females), mean age was (52.9 * 10.5 years). Group II included twenty five
diabetic patients without metabolic syndrome (20 males and 5 females), mean age was ( 55.8
± 9.1 years).Group III included twenty normal health volunteers serving as control (8 males
and 12 females),mean age was( 48.8 ± 4.2 years).Thorough history taking and clinical
examination was done to all subjects with stress on age of development of DM, duration of
DM, line of treatment, waist circumference, BMI, systolic and diastolic BP. The following
laboratory investigations were done to all subjects fasting and post prandial blood glucose
level, plasma insulin and adiponectin. Result: Plasma adiponectin level was significantly
lower in type 2 diabetic patients with metabolic syndrome compared to both type 2 diabetic
patients without metabolic syndrome and control group.The study showed a significant
negative correlation of adiponectin with body mass index( HMI), waist circumference,
systolic and diastolic blood pressure , fasting plasma glucose(FPG) and two hours post—
prandial plasma glucose(PPPG), triglyceride(TG), insulin and homeostasis model assessment
(HOMA) among group I patients. No significant correlation was elicited between adiponectin
level and these parameters in group II neither diabetic patients nor control group. A
significant positive correlation was detected between HDL-cholesterol and adiponectin in
diabetic patients with metabolic syndrome while no significant correlation was detected
between adiponectin and HDL-cholesterol in other groups.
.Conclusions: Hypoadiponectinemia can be considered as a cause and a component of
metabolic syndrome and it can be considered as a predictor of type 2 diabetes mellitus with
metabolic syndrome and not for type 2 diabetes mellitus without metabolic syndrome. |
